Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Biofrontera (BFRI) over the last 3 years, with Dec 2024 value amounting to $4,771.

  • Biofrontera's Gains from Sales and Divestitures rose 4615.99% to $225,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year increase of 4615.99%. This contributed to the annual value of $4,771 for FY2024, which is 44.45% down from last year.
  • As of FY2024, Biofrontera's Gains from Sales and Divestitures stood at $4,771, which was down 44.45% from $8,588 recorded in FY2023.
  • In the past 5 years, Biofrontera's Gains from Sales and Divestitures registered a high of $8,588 during FY2023, and its lowest value of $4,771 during FY2024.
  • For the 3-year period, Biofrontera's Gains from Sales and Divestitures averaged around $7,288, with its median value being $8,504 (2022).
  • Per our database at Business Quant, Biofrontera's Gains from Sales and Divestitures climbed by 0.99% in 2023 and then plummeted by 44.45% in 2024.
  • Yearly analysis of 3 years shows Biofrontera's Gains from Sales and Divestitures stood at $8,504 in 2022, then climbed by 0.99% to $8,588 in 2023, then plummeted by 44.45% to $4,771 in 2024.